輝瑞新冠口服藥獲附條件批準(zhǔn)上市

China's drug regulator on Friday granted conditional approval for the imports of Pfizer's Paxlovid COVID-19 pill.

2月11日，國(guó)家藥監(jiān)局附條件批準(zhǔn)輝瑞公司新冠病毒治療藥物奈瑪特韋片/利托那韋片組合包裝(即Paxlovid)進(jìn)口注冊(cè)。

The pill is a small-molecule oral drug, a co-package of antiviral drugs nirmatrelvir tablets and ritonavir tablets, for adults who are experiencing mild to moderate symptoms and who are at a higher risk of becoming more seriously ill, according to the National Medical Products Administration. It can be given to patients who, for instance, are older in age or have chronic renal diseases, diabetes, cardiovascular diseases, and chronic lung diseases.
國(guó)家藥監(jiān)局表示，Paxlovid屬小分子口服藥，可用于治療成人伴有進(jìn)展為重癥高風(fēng)險(xiǎn)因素的輕至中度新冠肺炎患者，例如伴有高齡、慢性腎臟疾病、糖尿病、心血管病、慢性肺病等重癥高風(fēng)險(xiǎn)因素的患者。